| 1.05 0.095 (9.96%) | 11-17 13:24 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.51 | 1-year : | 1.81 |
| Resists | First : | 1.29 | Second : | 1.54 |
| Pivot price | 1.21 |
|||
| Supports | First : | 0.87 | Second : | 0.73 |
| MAs | MA(5) : | 1.08 |
MA(20) : | 1.23 |
| MA(100) : | 1.3 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.6 |
D(3) : | 28 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 2.58 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RNXT ] has closed above bottom band by 18.9%. Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.06 - 1.07 | 1.07 - 1.07 |
| Low: | 0.88 - 0.89 | 0.89 - 0.9 |
| Close: | 0.94 - 0.96 | 0.96 - 0.97 |
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Tue, 17 Nov 2026
RenovoRx (RNXT) chairman buys shares, bringing direct holdings to 848,460. - Stock Titan
Wed, 11 Nov 2026
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
Thu, 05 Nov 2026
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 12 Aug 2026
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
Wed, 12 Aug 2026
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Tue, 28 Jul 2026
RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 865 (K) |
| Shares Short P.Month | 674 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | -368.5 % |
| Return on Assets (ttm) | -65 % |
| Return on Equity (ttm) | -125.3 % |
| Qtrly Rev. Growth | 115.4 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -3.36 |
| PEG Ratio | 0 |
| Price to Book value | 6.93 |
| Price to Sales | 25.34 |
| Price to Cash Flow | -4.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |